The International Immunotherapy Society for Fungal Diseases organizes to improve treatment outcomes for immunocompromised individuals with fungal diseases, suggesting a focus on immune therapies.
The treatment of invasive fungal diseases is unsatisfactory because of high morbidity and mortality despite antifungal therapy. These patients are often immunocompromised, and improvements in treatment outcome are likely to require immune therapy. To promote immune therapies against fungal diseases, the International Immunotherapy Society for Fungal Diseases was organized.
No takes yet. Share an insight, caveat, or question.
Casadevall et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: